See more : Nojima Corporation (7419.T) Income Statement Analysis – Financial Results
Complete financial analysis of Sage Therapeutics, Inc. (SAGE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sage Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Hamilton Lane Alliance Holdings I, Inc. (HLAHU) Income Statement Analysis – Financial Results
- SAB Biotherapeutics, Inc. (SABSW) Income Statement Analysis – Financial Results
- Daewoong Co., Ltd. (003090.KS) Income Statement Analysis – Financial Results
- Yaari Digital Integrated Services Limited (YAARII.NS) Income Statement Analysis – Financial Results
- AMG Advanced Metallurgical Group N.V. (AMVMF) Income Statement Analysis – Financial Results
Sage Therapeutics, Inc. (SAGE)
About Sage Therapeutics, Inc.
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 86.46M | 7.69M | 6.31M | 1.11B | 6.87M | 90.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.16M | 813.00K | 553.00K | 565.00K | 400.00K | 1.10M | 500.00K | 281.00K | 115.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 84.30M | 6.87M | 5.76M | 1.11B | 6.47M | 89.17M | -500.00K | -281.00K | -115.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 97.50% | 89.42% | 91.23% | 99.95% | 94.18% | 98.78% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 356.24M | 326.16M | 283.17M | 292.71M | 368.82M | 282.11M | 210.28M | 120.76M | 69.36M | 24.10M | 14.36M | 7.23M |
| General & Administrative | 274.52M | 227.70M | 183.50M | 196.95M | 345.78M | 201.40M | 62.88M | 39.41M | 25.29M | 9.71M | 3.38M | 2.40M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 44.60M | 11.18M | 5.27M | 3.08M | 0.00 | 0.00 | 0.00 |
| SG&A | 274.52M | 227.70M | 183.50M | 196.95M | 345.78M | 201.40M | 62.88M | 39.41M | 25.29M | 9.71M | 3.38M | 2.40M |
| Other Expenses | 33.39M | 15.00K | 134.00K | 250.00K | 82.00K | 22.00K | -64.00K | -35.00K | -23.00K | -9.00K | -3.00K | -1.00K |
| Operating Expenses | 664.15M | 553.86M | 466.66M | 489.67M | 714.59M | 483.51M | 273.16M | 160.16M | 94.65M | 33.81M | 18.28M | 9.63M |
| Cost & Expenses | 666.30M | 554.68M | 467.22M | 490.23M | 714.99M | 483.51M | 273.16M | 160.16M | 94.65M | 33.81M | 18.28M | 9.63M |
| Interest Income | 38.74M | 14.19M | 2.88M | 9.60M | 27.80M | 20.33M | 3.10M | 1.21M | 178.00K | 8.00K | 1.00K | 0.00 |
| Interest Expense | 0.00 | 14.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 1.39M | 1.12M | 4.18M | 2.63M | 2.28M | 1.10M | 500.00K | 281.00K | 115.00K | 51.00K | 47.00K | 44.00K |
| EBITDA | -545.07M | -545.87M | -456.73M | 626.60M | -705.84M | -392.10M | -269.62M | -160.16M | -94.65M | -33.81M | -18.23M | -9.59M |
| EBITDA Ratio | -630.47% | -7,116.69% | -7,306.74% | 58.49% | -10,310.48% | -435.61% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -579.85M | -546.99M | -460.91M | 596.23M | -708.12M | -393.24M | -273.16M | -160.16M | -94.65M | -33.81M | -18.28M | -9.63M |
| Operating Income Ratio | -670.69% | -7,116.69% | -7,306.74% | 53.51% | -10,310.48% | -435.61% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 38.36M | 14.21M | 3.02M | 9.85M | 27.89M | 20.36M | 3.04M | 1.18M | 155.00K | -1.00K | -2.00K | -1.00K |
| Income Before Tax | -541.49M | -532.78M | -457.89M | 606.07M | -680.24M | -372.88M | -270.12M | -158.99M | -94.50M | -33.81M | -18.28M | -9.63M |
| Income Before Tax Ratio | -626.32% | -6,931.88% | -7,258.91% | 54.40% | -9,904.46% | -413.06% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -29.52M | -7.07M | 15.52M | -30.09M | 20.36M | -3.63M | -1.49M | -293.00K | -59.00K | 2.00K | 0.00 |
| Net Income | -541.49M | -503.27M | -450.83M | 606.07M | -650.15M | -372.88M | -270.12M | -158.99M | -94.50M | -33.81M | -18.28M | -9.63M |
| Net Income Ratio | -626.32% | -6,547.84% | -7,146.91% | 54.40% | -9,466.38% | -413.06% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -9.05 | -8.49 | -7.68 | 11.66 | -12.79 | -8.08 | -7.09 | -4.75 | -3.40 | -1.57 | -1.09 | -0.57 |
| EPS Diluted | -9.05 | -8.49 | -7.68 | 11.43 | -12.79 | -8.08 | -7.09 | -4.75 | -3.40 | -1.57 | -0.73 | -0.39 |
| Weighted Avg Shares Out | 59.84M | 59.31M | 58.67M | 51.98M | 50.83M | 46.12M | 38.10M | 33.47M | 27.78M | 21.57M | 16.77M | 16.77M |
| Weighted Avg Shares Out (Dil) | 59.84M | 59.31M | 58.67M | 53.00M | 50.83M | 46.12M | 38.11M | 33.49M | 27.78M | 21.57M | 24.96M | 24.96M |
SAGE DEADLINE: RLF, A TOP-RANKED LAW FIRM, Encourages Sage Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 28 Deadline in Securities Class Action – SAGE
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sage Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAGE
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sage Therapeutics
Sage Therapeutics, Inc. Is Being Sued For Violating Securities Laws And Affected Shareholders Are Urged To Contact The Schall Law Firm
Sage Therapeutics to Reduce Workforce by 33%, Stock Down
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Sage Therapeutics, Inc. (SAGE)
The Schall Law Firm Encourages Investor Participation In A Securities Fraud Case Against Sage Therapeutics Inc
ROSEN, A TOP-RANKED LAW FIRM, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important October 28 Deadline in Securities Class Action – SAGE
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sage Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAGE
SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit
Source: https://incomestatements.info
Category: Stock Reports